Zelira Therapeutics Limited
OTC: ZLDAF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Oludare Odumosu
- Employees
- 8
- Headquarters
- Perth, Australia
- IPO year
- 2017
- Market cap
- $4.2M
- Website
- https://www.zeliratx.com
Loading ZLDAF…
Loading profile data…Frequently asked questions about ZLDAF
What does Zelira Therapeutics Limited (ZLDAF) do?
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabi...
Where does ZLDAF trade?
Zelira Therapeutics Limited (ZLDAF) trades on the Other OTC.
What sector is ZLDAF in?
Zelira Therapeutics Limited (ZLDAF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Zelira Therapeutics Limited?
Oludare Odumosu is the chief executive officer of Zelira Therapeutics Limited (ZLDAF).
Where is Zelira Therapeutics Limited headquartered?
Zelira Therapeutics Limited is headquartered in Australia.
Does ZLDAF pay a dividend?
Zelira Therapeutics Limited (ZLDAF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ZLDAF go public?
Zelira Therapeutics Limited (ZLDAF) completed its initial public offering in 2017.